Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation

Andrea Bacigalupo, Maria Pia Sormani, Teresa Lamparelli, Francesca Gualandi, Domenico Occhini, Stefania Bregante, Anna Maria Raiola, Carmen Di Grazia, Alida Dominietto, Elisabetta Tedone, Giovanna Piaggio, Marina Podesta, Barbara Bruno, Rosi Oneto, Anna Lombardi, Francesco Frassoni, Davide Rolla, Gianandrea Rollandi, Claudio Viscoli, Carlo FerroLucia Garbarino, Maria Teresa Van Lint

Research output: Contribution to journalArticle


Background and Objectives. Transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to be related to disease stage, duratiion of disease and type of donor. Furthermore, the outcome of transplants performed in the 1990s appears to be better than that of transplants done in the previous decade. The aims of this study were to determine whether these relationships still hold and whether the outcome of transplants is continuing to improve. Design and Methods. We analyzed 1180 consecutive patients with leukemia (n=979) or other hematologic malignancies (n=201) undergoing HSCT in 4 time periods: before 1990, 1991-1995, 1996-2000, and 2001-2002. Changes during these eras include increasing patient age, more unrelated transplants, more patients with advanced disease, different graft-versus-host disease (GvHD) prophylaxis, and different management of infections. Results. The actuarial 2-year transplant-related mortality (TRM) differed significantly between the transplant eras (p

Original languageEnglish
Issue number10
Publication statusPublished - Oct 2004



  • Allogeneic HSCT
  • Transplant related mortality

ASJC Scopus subject areas

  • Hematology

Cite this